WZ4002 - 10mM in DMSO, high purity , CAS No.1213269-23-8(DMSO), Inhibitor of BLK proto-oncogene; Src family tyrosine kinase;Inhibitor of Bruton tyrosine kinase;Inhibitor of epidermal growth factor receptor;Inhibitor of erb-b2 receptor tyrosine kinase 4;Inhibitor of IL2 inducible T cell kinase;Inhibitor of NUAK family
WZ4002 - 10mM in DMSO, high purity , CAS No.1213269-23-8(DMSO), Inhibitor of BLK proto-oncogene; Src family tyrosine kinase;Inhibitor of Bruton tyrosine kinase;Inhibitor of epidermal growth factor receptor;Inhibitor of erb-b2 receptor tyrosine kinase 4;Inhibitor of IL2 inducible T cell kinase;Inhibitor of NUAK family
WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I).
Storage Temp
Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Grade
Moligand™
Action Type
INHIBITOR
Mechanism of action
Inhibitor of BLK proto-oncogene; Src family tyrosine kinase;Inhibitor of Bruton tyrosine kinase;Inhibitor of epidermal growth factor receptor;Inhibitor of erb-b2 receptor tyrosine kinase 4;Inhibitor of IL2 inducible T cell kinase;Inhibitor of NUAK family
Product Description
Information
WZ4002 is a novel, mutant-selective EGFR inhibitor forEGFR(L858R)/(T790M)withIC50of 2 nM/8 nM in BaF3 cell line; does not inhibit ERBB2 phosphorylation (T798I). In vitro
WZ4002 inhibits other EGFR genotypes E746_A750 and E746_A750/T790M with IC50 of 2 and 6 nM. Besides, WZ4002 suppresses widetype ERBB2 with an IC50 of 32 nM. WZ4002 inhibits EGFR, AKT and ERK1/2 phosphorylation in NSCLC cell lines and WZ4002 prevents of EGFR phosphorylation in NIH-3T3 cells expressing different EGFR T790M mutant alleles. For WZ4002, kinases that exhibited greater than 95% inhibition relative to the DMSO control at 10 μM are selected for measurement of their dissociation constants. WZ4002, which possesses an ortho-methoxy group at the C2-aniline substituent, is more selective for EGFR compared to WZ3146. WZ4002 is 100-fold less effective at inhibiting phosphorylation of WT EGFR compared to the quinazoline inhibitors. Similarly, WZ4002 prevents EGFR kinase activity of recombinant L858R/T790M protein more potently than of WT EGFR, while the opposite is observed with HKI-272 and gefitinib. In addition, the phosphorylated EGFR of Src TKI-resistant H1975 cells, as well as HCC827 cells, is completely suppressed by the third generation EGFR TKI, WZ4002.
In vivo
In a 2-week efficacy study, WZ4002 treatment results in significant tumor regressions compared to vehicle alone in both T790M containing murine models. Treatment with low-dose WZ4002, and high-dose WZ4002 leads to mean decreases in tracer uptake of 26%, and 36%, respectively. Cell Data
